Trial Profile
A retrospective study evaluating the efficacy of gefitinib plus recombinant human endostatin (endostar) as a salvage therapy in patients with advanced non-small cell lung cancer who failed previous treatment with gefitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Nov 2017
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Gefitinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer